Home › Selling a Women’s Health Practice in 2026: Multiples, Named Buyers, and the OB-GYN MSO Playbook

Selling a Women’s Health Practice (2026): 6-12x EBITDA & OB-GYN MSO Playbook

Quick Answer

Christoph Totter · Managing Partner, CT Acquisitions

Buy-side M&A across 76+ active capital partners · Women’s health M&A: Axia / Unified / Pediatrix MSO playbook · Updated June 16, 2026

A US women’s health / OB-GYN practice in 2026 typically sells for roughly 6x to 12x EBITDA. Women’s health is a relatively new but rapidly-accelerating consolidation cycle driven by ancillary economics (in-office ultrasound, lab, fertility, aesthetics), value-based maternity care opportunity, and MFM (maternal-fetal medicine) sub-specialty value. By profile: single-MD OB-GYN ($500k-1.5M EBITDA) goes 5x-7x; multi-MD single-site or 2-3 location practice ($1.5-5M EBITDA) goes 6x-9x; small regional women’s health group ($3-10M EBITDA) goes 7x-10x; mid-size platform ($10-30M EBITDA, multi-site, MFM + fertility integration) goes 9x-11x; premium scale platform ($30M+ EBITDA, multi-state, comprehensive women’s health continuum) reaches 10x-12x+. Active buyers include Axia Women’s Health (Audax Group + Partners Group, the largest US women’s health MSO with ~500+ providers), Unified Women’s Healthcare (Altas Partners + KKR, multi-state with ~2,300 providers including MFM), Women’s Health USA (PE-backed), MEDNAX / Pediatrix Medical Group (NYSE: MD, MFM + neonatology focus), Privia Health (NASDAQ: PRVA, multi-specialty including OB-GYN), Inception Fertility (Lee Equity Partners + Morgan Stanley Capital, fertility-MSO adjacency), plus PE sponsors (Audax Group, Partners Group, Altas Partners, KKR, Lee Equity Partners, NMS Capital). The biggest multiple drivers are ancillary services integration (in-office ultrasound, lab, fertility, aesthetics, infusion), MFM (maternal-fetal medicine) subspecialty capability, fertility integration, value-based maternity care contracts, commercial payer mix, and APP scaling. Buyer-paid M&A advisory (CT Strategic Partners) costs the seller nothing.

If you own a US women’s health / OB-GYN practice in 2026, the M&A market is in a rapidly-accelerating consolidation cycle. Axia Women’s Health (Audax Group + Partners Group) leads at ~500+ providers. Unified Women’s Healthcare (Altas Partners + KKR) operates ~2,300 providers including MFM. Women’s Health USA, MEDNAX / Pediatrix (NYSE: MD), and Privia Health (NASDAQ: PRVA) compete. PE sponsors continue regional rollups.

What the asset is worth depends on three things: (1) ancillary services integration (in-office ultrasound, lab, fertility, aesthetics, infusion), (2) MFM (maternal-fetal medicine) subspecialty capability plus fertility integration, and (3) value-based maternity care positioning. This guide covers real multiples by profile, the named buyers transacting, and the operator-level diligence buyers will run.

Free Valuation Tool → Book a 30-Min Call Read: Broker Alternative

What this guide covers

Women’s health multiples 2026: 5x-7x for single-MD, 6x-9x for multi-MD, 7x-10x for small regional, 9x-11x for mid-size platforms, 10x-12x+ for premium scale with comprehensive continuum.
Active buyers: Axia Women’s Health (Audax Group + Partners Group, ~500+ providers, largest US women’s health MSO), Unified Women’s Healthcare (Altas Partners + KKR, ~2,300 providers including MFM), Women’s Health USA (PE), MEDNAX / Pediatrix Medical Group (NYSE: MD, MFM + neonatology), Privia Health (NASDAQ: PRVA, multi-specialty).
PE sponsor activity: Audax Group + Partners Group (Axia), Altas Partners + KKR (Unified), Lee Equity Partners (Inception Fertility), NMS Capital, Webster Equity Partners.
Multiple drivers: ancillary services integration (ultrasound, lab, fertility, aesthetics, infusion), MFM (maternal-fetal medicine) subspecialty capability, fertility integration, value-based maternity care contracts, commercial payer mix, APP scaling.
Things that compress: weak ancillary integration, owner-MD dependence, no MFM or fertility capability, weak commercial in-network status, single-state, OB liability claim history.
Sellers pay nothing on CT Strategic Partners’ buyer-paid advisory.

Women’s Health Practice Sale Multiples (2026)

Tier / Segment	Range (2026)
Solo / dual-MD practice	6.0x-8.0x EBITDA
Mid-size multi-MD practice	8.0x-10.0x EBITDA
PE-platform-ready with ancillary economics	10.0x-12.0x+ EBITDA
Ancillary services premium (ultrasound, lab, fertility, aesthetics)	+1.0x-2.0x EBITDA
Active buyer pool	Axia Women’s Health, Unified Women’s Healthcare (Altas), Pediatrix, Ob Hospitalist Group

Ranges reflect 2026 buy-side observations across active capital partners and named industry consolidators. Specific transaction outcomes vary by geography, customer concentration, and deal structure.

Named M&A transactions (2021-2025)

From the CT desk

What 2026 women’s health practice M&A activity reveals

•Axia Women’s Health (PE-backed since 2018, Altas Partners portfolio), Unified Women’s Healthcare (Altas Partners), Pediatrix Medical Group (NYSE: MD), Ob Hospitalist Group, plus 6+ regional women’s health MSOs absorbed announced women’s health practice acquisitions in 2026, with median EBITDA multiples 8.0x-12.0x for $2M+ EBITDA targets.
•Women’s health is a relatively new but rapidly-accelerating consolidation cycle driven by ancillary economics (in-office ultrasound, laboratory, fertility services, aesthetics, medical weight management), value-based maternity care opportunity (CMS Maternity Care Action Plan, commercial-payor capitated maternity bundles), and MFM (maternal-fetal medicine) subspecialty consolidation.
•Solo / dual-MD practices with high owner-MD brand dependency compress 2x-3x EBITDA versus multi-MD practices. Multi-MD practices with documented patient-list portability across the physician roster plus 3-5 year MD retention agreements clear platform-tier multiples.
•Ancillary economics drive 1x-2x EBITDA premium. Practices with documented in-office ultrasound + on-site lab + fertility consultation + medical aesthetics + medical weight management revenue percentages (above 25% combined ancillary revenue) attract PE platform interest specifically because ancillary economics scale predictably in MSO context.

Related Cluster GuideFor the broader medical-practice companion on how to sell a medical practice, see our reference.

For 2026 how to sell a medical practice with 5x-12x EBITDA by specialty, named PE consolidators (Optum, USPI), and Stark / Anti-Kickback diligence, see our reference guide.

For 2026 cardiology practice sale playbook (MSO buyers) with 6x-12x EBITDA multiples and named MSO buyers (US Heart & Vascular, CVA, US Cardiology Partners), see our guide.

For 2026 dermatology MSO sale playbook with 5x-14x EBITDA multiples and named buyers (Schweiger, Forefront, Advanced, Pinnacle), see our guide.

For the 2026 inventory of dermatology MSO PE platforms with 35+ named PE-backed MSOs, see our buyer-tracker guide.

Target	Buyer	Year	What it tells us
Unified Women’s Healthcare KKR investment	KKR (with Altas Partners)	2024	Major PE investment in largest US women’s health MSO.
Axia Women’s Health continued growth	Audax Group + Partners Group	2022-2025	Major women’s health MSO continues aggressive tuck-in M&A.
Multiple regional women’s health tuck-ins	Various PE platforms	2022-2025	PE sponsors continue women’s health consolidation.
MEDNAX / Pediatrix MFM expansion	MEDNAX / Pediatrix (NYSE: MD)	2022-2025	Public MFM + neonatology specialist continues organic and acquisitive growth.
Privia Health OB-GYN segment growth	Privia Health (NASDAQ: PRVA)	2022-2025	Multi-specialty MSO continues OB-GYN segment expansion.

The named buyer landscape

PE-backed national women’s health MSOs

Unified Women’s Healthcare (Altas Partners + KKR) — ~2,300 providers including MFM, the largest US women’s health MSO.
Axia Women’s Health (Audax Group + Partners Group) — ~500+ providers, multi-state OB-GYN focus.
Women’s Health USA (PE-backed) — multi-state platform.

MFM + neonatology specialists

MEDNAX / Pediatrix Medical Group (NYSE: MD) — public MFM + neonatology + pediatric specialist group.

Multi-specialty MSO (OB-GYN segment)

Privia Health (NASDAQ: PRVA) — multi-specialty MSO with OB-GYN segment.

Fertility adjacency

Inception Fertility (Lee Equity Partners + Morgan Stanley Capital) — fertility MSO adjacent to women’s health.
Plus other PE-backed fertility platforms (US Fertility, Pinnacle Fertility, Kindbody).

PE sponsors active in this space

Audax Group + Partners Group (Axia Women’s Health), Altas Partners + KKR (Unified Women’s Healthcare), Lee Equity Partners (Inception Fertility), NMS Capital, Webster Equity Partners.

What each buyer will pay for vs. what they reject

Will pay premium for: ancillary services integration (in-office ultrasound, lab, fertility, aesthetics including hormone replacement and aesthetic injectables, infusion for high-risk OB), MFM subspecialty capability, fertility integration, named value-based maternity care contracts (commercial maternity bundles, Medicaid bundled payment), commercial payer mix 55%+, advanced practice provider (APP) scaling (CNMs, WHNPs), modern EMR.
Will compress or reject: weak ancillary integration, owner-MD dependence, OB malpractice claim history, single-state operations, Medicaid-heavy payer mix without commercial diversification, weak APP scaling, no MFM or fertility capability.

The operator-level KPI playbook buyers will diligence

Case mix

Annual deliveries (OB volume).
GYN office visit volume.
Surgery volume (hysterectomy, oophorectomy, prolapse repair).
Robotic GYN surgery volume (da Vinci).
Ultrasound and prenatal imaging volume.
Fertility cycles if integrated.

Ancillary services

In-office ultrasound (level 1 and level 2 maternal-fetal ultrasound).
Lab integration.
Fertility services if integrated.
Aesthetic services (hormone replacement, aesthetic injectables, vaginal rejuvenation).
Infusion for high-risk OB.

Payer mix

Commercial percentage: 55%+ benchmark.
Medicaid percentage: Often higher in OB (varies by market).
Value-based maternity contracts.

Provider bench

MD count and subspecialty (general OB-GYN, MFM, REI, gyn oncology, urogyn).
APP scaling (CNMs, WHNPs, PAs).
Hospital privileging and deliveries.
Equity-rollover expectations.

Dangers and traps

1. OB malpractice claim history

OB has elevated malpractice exposure; document claims, settlements, and current coverage.

2. Weak ancillary integration

Ultrasound, lab, fertility, aesthetics integration are major multiple-builders.

3. Owner-MD dependence

Build MD/APP bench.

4. Medicaid-heavy payer mix

Commercial diversification matters.

5. No MFM or fertility capability

MFM and fertility integration are premium revenue.

6. Single-state operations

Multi-state platform path matters.

7. Hospital privileging and delivery model risk

Delivery hospital relationships are critical infrastructure.

8. State abortion law variance post-Dobbs

State regulatory variance affects operations in some markets.

Our POV in 2026

Women’s health M&A is rapidly accelerating. Unified Women’s Healthcare (Altas Partners + KKR) leads at ~2,300 providers including MFM. Axia Women’s Health (Audax Group + Partners Group), Women’s Health USA, MEDNAX/Pediatrix, and Privia Health compete. PE sponsors continue regional rollups.

The right time to prepare is 12-18 months before going to market — integrate ancillaries, build MFM or fertility capability, develop value-based maternity contracts.

Preparing your business for sale: 12-18 months out

Get multi-year audited financials.
Integrate ancillaries (ultrasound, lab, fertility, aesthetics, infusion).
Build MFM subspecialty capability if not present.
Integrate fertility if applicable.
Develop value-based maternity care contracts.
Confirm commercial in-network status.
Scale APPs (CNMs, WHNPs).
Document OB malpractice claim history and coverage.
Modernize EMR.
Run a competitive process. Axia Women’s Health (Audax Group + Partners Group), Unified Women’s Healthcare (Altas Partners + KKR), Women’s Health USA, MEDNAX / Pediatrix Medical Group, Privia Health, plus PE sponsors directly.

About the Author

Christoph Totter is the founder of CT Acquisitions, a buy-side partner headquartered in Sheridan, Wyoming. We work directly with 76+ buyers, search funders, family offices, lower middle-market PE, and strategic consolidators, including direct mandates with the largest home services consolidators that other intermediaries can’t access. The buyers pay us when a deal closes, not the seller. No retainer, no exclusivity, no contract until close. Connect on LinkedIn · Get in touch

Free, No Email Required

Get a personalized valuation in 90 seconds

Answer six quick questions and we’ll give you a sector-adjusted EBITDA multiple range plus the specific factors driving your number up or down.

Open the Valuation Tool →

The five pillars of how CT Acquisitions works

$0 to Sellers

Buyer pays our fee. Founders never write a check.

No Retainer

No engagement letter. No upfront cost. No exclusivity contract.

100+ Capital Partners

Search funders, family offices, lower-middle-market PE, strategics.

Sequential, Not Auction

Confidential introductions to the right buyers. No bidding war.

60-120 Day Close

Not 9-12 months. Not 18 months. Months, not years.

No Pitch · No Pressure

Ready to start a confidential conversation?

Tell us about your business. We’ll tell you what it’s likely worth, whether we have qualified buyers in our network, and what the next 60-120 days could look like. No engagement letter. No retainer. Walk at any time.

Start a Confidential Conversation →

Frequently asked questions

What is the typical multiple for a women’s health / OB-GYN practice in 2026?

Single-MD OB-GYN practices ($500k-1.5M EBITDA) typically sell at 5x-7x EBITDA. Multi-MD single-site or 2-3 location practices ($1.5-5M EBITDA) go 6x-9x. Small regional women’s health groups ($3-10M EBITDA) go 7x-10x. Mid-size platforms ($10-30M EBITDA, multi-site, MFM + fertility integration) go 9x-11x. Premium scale platforms ($30M+ EBITDA, multi-state, comprehensive women’s health continuum) reach 10x-12x+.

Who are the active buyers of women’s health practices right now?

PE-backed national women’s health MSOs: Unified Women’s Healthcare (Altas Partners + KKR, ~2,300 providers including MFM, largest US women’s health MSO), Axia Women’s Health (Audax Group + Partners Group, ~500+ providers), Women’s Health USA (PE). MFM + neonatology specialists: MEDNAX / Pediatrix Medical Group (NYSE: MD). Multi-specialty: Privia Health (NASDAQ: PRVA, OB-GYN segment). Fertility adjacency: Inception Fertility (Lee Equity Partners + Morgan Stanley Capital). PE sponsors: Audax Group + Partners Group, Altas Partners + KKR, Lee Equity Partners, NMS Capital, Webster Equity Partners.

What hurts a women’s health practice’s valuation most?

OB malpractice claim history (OB has elevated exposure), weak ancillary integration (ultrasound, lab, fertility, aesthetics are major multiple-builders), owner-MD dependence, Medicaid-heavy payer mix without commercial diversification, weak APP scaling, no MFM or fertility capability, hospital privileging risk on delivery model, and state regulatory variance post-Dobbs in some markets.

Why is MFM (maternal-fetal medicine) so important in valuation?

Maternal-fetal medicine is the high-risk OB subspecialty handling complex pregnancies (multiple gestation, diabetes, hypertension, fetal anomalies). MFM commands premium reimbursement, requires specialized equipment (high-resolution ultrasound, fetal MRI access), and creates referral-network value. Women’s health platforms with MFM capability achieve premium multiples. Unified Women’s Healthcare’s MFM integration is a key differentiator vs. pure OB-GYN MSOs.

Do I have to pay a broker fee?

No. CT Strategic Partners runs a buyer-paid M&A advisory model. The seller pays nothing.

How long does it take to sell a women’s health practice?

Typical process 5-9 months. Add 12-18 months of preparation.

What is value-based maternity care?

Value-based maternity care contracts (commercial maternity bundles, Medicaid bundled payment, episode-of-care reimbursement) reward operators for delivering total prenatal-to-postpartum care at fixed price with quality metrics (cesarean rate, preterm birth, NICU admission). Women’s health platforms with documented value-based maternity participation capture upside and demonstrate the scale + analytics required for premium multiples.

When should I start preparing if I plan to sell in 2027 or 2028?

12-18 months before going to market. Highest-leverage work: integrate ancillaries, build MFM or fertility capability, develop value-based maternity contracts, scale APPs.